Skip to main content

Yusimry

Pronunciation: Ue-sim-ree
Generic name: adalimumab-aqvh
Dosage form: subcutaneous injection
Drug class: TNF alfa inhibitors

Medically reviewed by Melisa Puckey, BPharm. Last updated on Oct 26, 2023.

What is Yusimry?

Yusimry is a biosimilar of Humira; it is a TNF alfa inhibitor used to reduce pain, inflammation, and skin symptoms in chronic autoimmune conditions. Yusimry is used to treat rheumatoid arthritis (RA), psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, ankylosing spondylitis, and uveitis.

Yusimry (adalimumab-aqvh) is a biosimilar to Humira, biosimilars are biologic medicines that are a very close copy to the original product made by another company. It is not an interchangeable biosimilar.

Yusimry is available as Yusimry Pen, which is a single-dose prefilled pen (40 mg/0.8mL) and also a Single-dose prefilled glass syringe (40 mg/0.8 mL).

How does Yusimry work?

Normally, your immune system defends your body against diseases by fighting harmful bacteria or viruses. However, in autoimmune disorders, the immune system becomes hyperactive and mistakenly attacks its own tissues, leading to symptoms of the autoimmune condition. Tumor necrosis factor (TNF) is a protein that is involved in causing inflammation. Yusimry works as a TNF blocker that inhibits TNF, helping to reduce pain, inflammation, and skin symptoms. Yusimry is a recombinant human monoclonal antibody.

What is Yusimry used for?

Yusimry is FDA-approved to be used to treat the signs and symptoms of: 

Rheumatoid arthritis (adults) that is active and moderate to severe, it can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 

Juvenile idiopathic arthritis (moderate to severe polyarticular) for children 2 years and older, to be used alone or with methotrexate.

Psoriatic arthritis in adults to be used alone or with other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

Ankylosing spondylitis (AS) in adults.

Hidradenitis suppurativa (moderate to severe) in adults. 

Crohn’s disease (moderate to severe) in patients 6 years of age and older. 

Ulcerative colitis (moderate to severe) in adults. It is not known whether Yusimry is effective in people who stopped responding to or could not tolerate TNF-blocker medicines. 

Plaque psoriasis (chronic and severe) in adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills), and when other systemic therapies are medically less appropriate.

Uveitis (UV) for non-infectious intermediate, posterior, and panuveitis in adult patients.

Warnings 

Yusimry affects your immune system. You may get infections more easily, even serious or fatal infections.

Before or during treatment with Yusimry, tell your doctor if you have signs of infection such as fever, chills, aches, tiredness, cough, skin sores, diarrhea, or burning when you urinate.

Your doctor should test you for tuberculosis (TB) before you start taking Yusimry and monitor you closely for signs and symptoms of TB during treatment.

The chances of getting cancer may be increased for children and adults taking TNF-blockers.

Before taking this medicine

Before you start using Yusimry, tell your doctor if you have signs of infection - fever, chills, sweats, muscle aches, tiredness, cough, bloody mucus, skin sores, diarrhea, burning when you urinate, or feeling constantly tired.

Yusimry should only be used in age groups for the specific conditions that Yusimry is FDA-approved to treat. Children using Yusimry should be current on all childhood immunizations before starting treatment.

Tell your doctor if you have ever had:

Tell your doctor where you live and if you have recently traveled or plan to travel. You may be exposed to infections that are common in certain areas of the world.

Yusimry may cause a rare type of lymphoma (cancer) of the liver, spleen, and bone marrow that can be fatal. This has occurred mainly in teenagers and young men with Crohn's disease or ulcerative colitis. However, anyone with an inflammatory autoimmune disorder may have a higher risk of lymphoma. Talk with your doctor about your own risk.

Pregnancy

It is not known whether Yusimry will harm an unborn baby. Tell your doctor if you are pregnant or planning a pregnancy. Make sure any doctor caring for your newborn baby knows if you used this medicine while you were pregnant, and especially before your baby receives any vaccines.

Breastfeeding

It may be unsafe to breastfeed a baby while using Yusimry. Ask your doctor about any risks and the best way to feed your baby while on this medicine.

How should I use Yusimry?

Use Yusimry exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.

Yusimry is injected under the skin (subcutaneous injection) using an autoinjector or a prefilled syringe.

The dose schedule for Yusimry depends on the severity and the condition you are treating. Follow your doctor's dosing instructions very carefully.

A healthcare provider will teach you how to use this medicine by yourself properly. Do not inject this medicine if you do not fully understand the instructions for proper use. Ask your doctor or pharmacist if you have any questions.

Do not use this medicine if you have any signs of an infection. Call your doctor for instructions.

Prepare your injection only when you are ready to give it. Do not use it if the medicine looks cloudy, has changed color, or has particles in it. Call your pharmacist for new medicine.

Leave the auto-injector or prefilled syringe at room temperature for 15 to 30 minutes to allow it to warm up.  Do not warm the prefilled syringe using heat sources such as hot water or a microwave.

Choose an injection site. You may inject into the front of your thighs, and your abdomen except for the 2 in (5 cm) around the belly button (navel). Rotate the injection site each time you give an injection. Each new injection site should be at least 1.2 in (3 cm) away from the injection site you used before.

Do not inject into skin that is red, hard, tender, damaged, bruised, or scarred, and do NOT inject through your clothes.

Yusimry affects your immune system so you may get infections more easily, even serious or fatal infections. Your doctor will need to examine you on a regular basis.

Use a needle and syringe only once, then place them in a puncture-proof "sharps" container. Follow state or local laws about how to dispose of this container. Keep it out of the reach of children and pets.

Dosing information

Yusimry is available as: 

The dose and frequency of Yusimry given is dependent on age, severity, and condition treated. For more information on specific dosing schedules, click the link below.

Entyvio, Otezla, Cimzia, Stelara, prednisone, naproxen, methotrexate, triamcinolone ophthalmic, dexamethasone, dexamethasone ophthalmic

What happens if I miss a dose?

Use the medicine as soon as you remember, and then go back to your regular injection schedule. Do not use extra medicine to make up for the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while using Yusimry?

Do not inject into skin that is bruised, red, tender, or hard.

Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.

Do not receive a "live" vaccine while using Yusimry. The vaccine may not work as well during this time, and may not fully protect you from disease. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), or zoster (shingles).

Yusimry side effects

Get emergency medical help if you have any of these signs of an allergic reaction to Yusimry: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor right away if you have any symptoms of lymphoma:

Also call your doctor at once if you have:

Older adults may be more likely to develop infections or cancer while using Yusimry.

Common side effects of Yusimry may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088

What other drugs will affect Yusimry ?

Some drugs should not be used together with Yusimry. Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Yusimry especially:

Avoid the use of live vaccines.

This list is not complete. Other drugs may interact with including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed.

Does Yusimry interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Storage

Store in the refrigerator at 36ºF to 46ºF (2ºC to 8ºC). 

Store in the original carton until use to protect it from light. 

Do not freeze. Do not use Yusimry if frozen, even if it has been thawed.

Storage during traveling:

Ingredients

Yusimry Active ingredient: adalimumab-aqvh

Inactive ingredients: glycine, L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sodium chloride, and Water for Injection. Sodium hydroxide is added as necessary to adjust the pH. 

Manufacturer

Manufactured by: Coherus BioSciences, Inc., Redwood City, California 94065, USA

Yusimry Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Yusimry.

Humira (adalimumab) - AbbVie Inc.
Formulation type Strength
Autoinjector 40 mg/0.4 mL
Autoinjector 40 mg/0.8 mL
Autoinjector 80 mg/0.8 mL
Pre-Filled Syringe 10 mg/0.1 mL
Pre-Filled Syringe 10 mg/0.2 mL Discontinued
Pre-Filled Syringe 20 mg/0.2 mL
Pre-Filled Syringe 20 mg/0.4 mL Discontinued
Pre-Filled Syringe 40 mg/0.4 mL
Pre-Filled Syringe 40 mg/0.8 mL
Pre-Filled Syringe 80 mg/0.8 mL
Single-Dose Vial 40 mg/0.8 mL

View Humira information in detail.

Humira interchangeable products

Interchangeable biosimilar products can be dispensed by a pharmacist without the intervention of the prescriber of the reference product.

Pharmacy laws for biosimilar prescribing may vary by state.

Abrilada (adalimumab-afzb) - Pfizer Inc.
Formulation type Strength
Autoinjector 40 mg/0.8 mL
Pre-Filled Syringe 10 mg/0.2 mL Discontinued
Pre-Filled Syringe 20 mg/0.4 mL
Pre-Filled Syringe 40 mg/0.8 mL
Single-Dose Vial 40 mg/0.8 mL

View Abrilada information in detail.

Amjevita (adalimumab-atto) - Amgen Inc.
Formulation type Strength
Autoinjector 40 mg/0.8 mL
Pre-Filled Syringe 10 mg/0.2 mL
Pre-Filled Syringe 20 mg/0.4 mL
Pre-Filled Syringe 40 mg/0.8 mL

View Amjevita information in detail.

Cyltezo (adalimumab-adbm) - Boehringer Ingelheim Pharmaceuticals, Inc.
Formulation type Strength
Autoinjector 40 mg/0.8 mL
Pre-Filled Syringe 10 mg/0.2 mL
Pre-Filled Syringe 20 mg/0.4 mL
Pre-Filled Syringe 40 mg/0.8 mL

View Cyltezo information in detail.

Hadlima (adalimumab-bwwd) - Samsung Bioepis Co., Ltd.
Formulation type Strength
Pre-Filled Syringe 40 mg/0.8 mL
Single-Dose Vial 40 mg/0.8 mL

View Hadlima information in detail.

Hyrimoz (adalimumab-adaz) - Sandoz Inc.
Formulation type Strength
Pre-Filled Syringe 10 mg/0.1 mL
Pre-Filled Syringe 10 mg/0.2 mL Discontinued
Pre-Filled Syringe 20 mg/0.2 mL
Pre-Filled Syringe 20 mg/0.4 mL
Pre-Filled Syringe 40 mg/0.8 mL
Pre-Filled Syringe 80 mg/0.8 mL

View Hyrimoz information in detail.

Simlandi (adalimumab-ryvk) - Alvotech USA Inc.
Formulation type Strength
Autoinjector 40 mg/0.4 mL
Pre-Filled Syringe 40 mg/0.4 mL

View Simlandi information in detail.

Humira biosimilar products

Biosimilar products can only be dispensed in place of the reference product if the healthcare provider specifically prescribes the biosimilar product by name.

Pharmacy laws for biosimilar prescribing may vary by state

Amjevita (adalimumab-atto) - Amgen Inc.
Formulation type Strength
Autoinjector 40 mg/0.4 mL
Autoinjector 80 mg/0.8 mL
Pre-Filled Syringe 20 mg/0.2 mL
Pre-Filled Syringe 40 mg/0.4 mL
Pre-Filled Syringe 80 mg/0.8 mL

View Amjevita information in detail.

Cyltezo (adalimumab-adbm) - Boehringer Ingelheim Pharmaceuticals, Inc.
Formulation type Strength
Autoinjector 40 mg/0.4 mL
Pre-Filled Syringe 40 mg/0.4 mL

View Cyltezo information in detail.

Hadlima (adalimumab-bwwd) - Samsung Bioepis Co., Ltd.
Formulation type Strength
Autoinjector 40 mg/0.4 mL
Autoinjector 40 mg/0.8 mL
Pre-Filled Syringe 40 mg/0.4 mL

View Hadlima information in detail.

Hulio (adalimumab-fkjp) - Biocon Biologics Inc.
Formulation type Strength
Autoinjector 40 mg/0.8 mL
Pre-Filled Syringe 20 mg/0.4 mL
Pre-Filled Syringe 40 mg/0.8 mL

View Hulio information in detail.

Hyrimoz (adalimumab-adaz) - Sandoz Inc.
Formulation type Strength
Autoinjector 40 mg/0.4 mL
Autoinjector 40 mg/0.8 mL
Autoinjector 80 mg/0.8 mL
Pre-Filled Syringe 40 mg/0.4 mL

View Hyrimoz information in detail.

Idacio (adalimumab-aacf) - Fresenius Kabi USA, LLC
Formulation type Strength
Autoinjector 40 mg/0.8 mL
Pre-Filled Syringe 40 mg/0.8 mL
Single-Dose Vial 40 mg/0.8 mL

View Idacio information in detail.

Simlandi (adalimumab-ryvk) - Alvotech USA Inc.
Formulation type Strength
Pre-Filled Syringe 20 mg/0.2 mL
Pre-Filled Syringe 80 mg/0.8 mL

View Simlandi information in detail.

Yuflyma (adalimumab-aaty) - CELLTRION, Inc.
Formulation type Strength
Autoinjector 40 mg/0.4 mL
Autoinjector 80 mg/0.8 mL
Pre-Filled Syringe 20 mg/0.2 mL
Pre-Filled Syringe 40 mg/0.4 mL
Pre-Filled Syringe 80 mg/0.8 mL

View Yuflyma information in detail.

Yusimry (adalimumab-aqvh) - Hong Kong King-Friend Industrial Company Limited
Formulation type Strength
Autoinjector 40 mg/0.8 mL
Pre-Filled Syringe 40 mg/0.8 mL

Popular FAQ

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. One example is Amjevita (adalimumab-atto), the first biosimilar approved for Humira (adalimumab) in 2016. Continue reading

Can you take Humira with antibiotics?

You can take Humira with an antibiotic if your doctor has prescribed both of these medications for you. There may be some antibiotics that are not safe to take with Humira, so do not start taking any antibiotic without prior approval from your doctor. Continue reading

Cosentyx vs Humira: How do they compare?

Both Cosentyx and Humira are available as subcutaneous injections (which means given under the skin) and may be used to treat certain inflammatory conditions such as plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and ankylosing spondylitis. Cosentyx is also available as an IV injection that can be administered by a healthcare provider. After an initial loading dose, Humira is given every two weeks and Cosentyx every four weeks. Continue reading

Skyrizi vs Humira for plaque psoriasis - How do they compare?

In a head-to-head clinical study between Skyrizi and Humira, researchers found that Skyrizi was better than Humira at clearing moderate-to-severe plaque psoriasis in adults. At 16 weeks, 72% of patients given Skyrizi achieved 90% clearer skin compared to 47% of patients given Humira, a statistically significant outcome. Continue reading

Is Amjevita interchangeable with Humira?

Amjevita is not yet interchangeable with Humira, and the pharmacist must get approval from your doctor before they can substitute it for Humira. To date, the approved interchangeable biosimilars for Humira are Abrilada, Cyltezo, Hyrimoz, and Simlandi, according to the FDA Purple Book as of April 2024. Continue reading

More FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.